Onvansertib is an investigational oral enzyme inhibitor targeting PLK1 in oncology. Ongoing studies are evaluating it across multiple cancers, including small cell lung cancer and other solid tumors. It is currently in active clinical trial development and not approved as a marketed therapy.
New combination therapies demonstrate improved outcomes in advanced anal and colorectal cancers, with retifanlimab plus chemotherapy approved for anal cancer and onvansertib showing strong efficacy signals in RAS-mutated colorectal cancer.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06736717 |
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT06398587 |
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma |
WITHDRAWN | PHASE2 |
| NCT06106308 |
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05593328 |
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation |
COMPLETED | PHASE2 |
| NCT05549661 |
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms |
RECRUITING | PHASE1 |
| NCT05450965 |
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer |
RECRUITING | PHASE2 |
| NCT05383196 |
Onvansertib + Paclitaxel In TNBC |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT04752696 |
Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma |
COMPLETED | PHASE2 |
| NCT04446793 |
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer |
NO_LONGER_AVAILABLE | |
| NCT04005690 |
Targeted Pathway Inhibition in Patients With Pancreatic Cancer |
RECRUITING | EARLY_PHASE1 |
